PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 19428345-7 2009 Our study showed that esculetin, PD98059 (MEK/ERK inhibitor), and SP600125 (JNK inhibitor) similarly enhanced the As(2)O(3)-induced GSH depletion. Arsenic Trioxide 114-123 mitogen-activated protein kinase kinase 7 Homo sapiens 42-45 19428345-14 2009 Based on these studies, esculetin enhances the As(2)O(3)-provoked apoptosis by modulating the MEK/ERK and JNK pathways and reducing intracellular GSH levels. Arsenic Trioxide 47-56 mitogen-activated protein kinase kinase 7 Homo sapiens 94-97 16283431-5 2006 The As2O3-induced p21 activation was attenuated by inhibitors of EGFR and MEK in a dose-dependent manner. Arsenic Trioxide 4-9 mitogen-activated protein kinase kinase 7 Homo sapiens 74-77 18583568-0 2008 Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways. Arsenic Trioxide 58-61 mitogen-activated protein kinase kinase 7 Homo sapiens 10-13 17168655-8 2006 Our pre-clinical studies showed that ATO is capable to induce cell death in acute leukemia cells but the apoptotic function is limited since it can induce also a mechanism of cell defense by activating pro-survival molecules such as MEK-ERK, Bcl-xL, Bcl-2. Arsenic Trioxide 37-40 mitogen-activated protein kinase kinase 7 Homo sapiens 233-236 17168655-9 2006 By combining ATO with specific MEK inhibitors, we demonstrated that the block of MEK-ERK phosphorylation, the induction of Bad de-phosphorylation, and activation of p53AIP1 apoptotic pathway interrupt the pro-survival mechanisms of ATO and kill the leukemic cells by apoptotic synergism. Arsenic Trioxide 13-16 mitogen-activated protein kinase kinase 7 Homo sapiens 81-84 18583568-1 2008 We demonstrate that blockade of the MEK/ERK signaling module, using the small-molecule inhibitors PD184352 or PD325901 (PD), strikingly enhances arsenic trioxide (ATO)-induced cytotoxicity in human myeloma cell lines (HMCLs) and in tumor cells from patients with multiple myeloma (MM) through a caspase-dependent mechanism. Arsenic Trioxide 145-161 mitogen-activated protein kinase kinase 7 Homo sapiens 36-39 18583568-1 2008 We demonstrate that blockade of the MEK/ERK signaling module, using the small-molecule inhibitors PD184352 or PD325901 (PD), strikingly enhances arsenic trioxide (ATO)-induced cytotoxicity in human myeloma cell lines (HMCLs) and in tumor cells from patients with multiple myeloma (MM) through a caspase-dependent mechanism. Arsenic Trioxide 163-166 mitogen-activated protein kinase kinase 7 Homo sapiens 36-39 16283431-9 2006 Furthermore, MEK inhibitor attenuated the anti-tumor effect of As2O3. Arsenic Trioxide 63-68 mitogen-activated protein kinase kinase 7 Homo sapiens 13-16 16445569-6 2005 It was found that As2O3 activates the prosurvival mitogen-activated protein kinase kinase (MEK)/ERK pathway in MCF-7 cells, which, conversely, may compromise the efficacy of As2O3. Arsenic Trioxide 18-23 mitogen-activated protein kinase kinase 7 Homo sapiens 91-94 16445569-6 2005 It was found that As2O3 activates the prosurvival mitogen-activated protein kinase kinase (MEK)/ERK pathway in MCF-7 cells, which, conversely, may compromise the efficacy of As2O3. Arsenic Trioxide 174-179 mitogen-activated protein kinase kinase 7 Homo sapiens 91-94 15843040-4 2005 While ERK1/2 activation was a general phenomenon, irrespective of the used cell type or antitumour drug, the MEK/ERK inhibitors only reduced cisplatin toxicity in human myeloid cells (THP-1, HL-60 and NB-4), but not in RAW 264.7 mouse macrophages and NRK-52E rat renal tubular cells; and failed to reduce the toxicity etoposide, camptothecin, melphalan and arsenic trioxide, in U-937 cells. Arsenic Trioxide 357-373 mitogen-activated protein kinase kinase 7 Homo sapiens 109-112 16101455-7 2005 Nevertheless, MEK blockade efficiently and selectively sensitizes leukemic cells to sub-optimal doses of other apoptotic stimuli, including classical cytotoxics (nucleoside analogs, microtubule-targeted drugs, gamma-irradiation), biologicals (retinoids, interferons, arsenic trioxide), and, most interestingly, other signal transduction/apoptosis modulators (UCN-01, STI571, Bcl-2 antagonists). Arsenic Trioxide 267-283 mitogen-activated protein kinase kinase 7 Homo sapiens 14-17 20615082-4 2010 ATO augmented ATRA-induced RAF/MEK/ERK axis signaling, expression of CD11b and p47(PHOX), and inducible oxidative metabolism. Arsenic Trioxide 0-3 mitogen-activated protein kinase kinase 7 Homo sapiens 31-34 20592496-8 2010 Additionally, treatment with As(2)O(3) in combination with inhibitors specific for MEK (U0126) in HOS and MNNG cells resulted in a marked inhibition of cell invasion and As(2)O(3) could significantly reduce PMA-induced invasion. Arsenic Trioxide 170-179 mitogen-activated protein kinase kinase 7 Homo sapiens 83-86 23548265-6 2013 Comparable ATO-sensitizing effects were also found with PI3K/AKT and mitogen-activated protein/extracellular signal-regulated kinase (MEK) inhibitors, suggesting an essential role of the EGFR-mediated downstream signaling pathway in cancer cell protection against ATO. Arsenic Trioxide 11-14 mitogen-activated protein kinase kinase 7 Homo sapiens 69-132 23548265-6 2013 Comparable ATO-sensitizing effects were also found with PI3K/AKT and mitogen-activated protein/extracellular signal-regulated kinase (MEK) inhibitors, suggesting an essential role of the EGFR-mediated downstream signaling pathway in cancer cell protection against ATO. Arsenic Trioxide 11-14 mitogen-activated protein kinase kinase 7 Homo sapiens 134-137 22293863-6 2012 The MEK inhibitor decreased O2 - levels in ATO-treated HPF cells whereas JNK and p38 inhibitors generally increased ROS levels including O2 - in these cells. Arsenic Trioxide 43-46 mitogen-activated protein kinase kinase 7 Homo sapiens 4-7 19846917-8 2009 The treatment with MAP kinase kinase (MEK), c-Jun N-terminal kinase (JNK) and p38 inhibitors intensified the cell growth inhibition, cell death, MMP (DeltaPsi(m)) loss, and GSH depletion in the ATO-treated Calu-6 cells. Arsenic Trioxide 194-197 mitogen-activated protein kinase kinase 7 Homo sapiens 19-36